PR Newswire Clinical TrialsOriginal article
Galibra Neuroscience Receives FDA Orphan Drug and Rare Pediatric Disease Designations for SSADH Deficiency Gene Therapy
RegulatorySSADH Deficiency Gene TherapyPositive
AI Analysis
Summary
Galibra Neuroscience received FDA Orphan Drug Designation and Rare Pediatric Disease Designation for its SSADH Deficiency gene therapy, a potential first disease-modifying treatment for this ultra-rare neurometabolic disorder.
Outcome Details
Received Orphan Drug Designation and Rare Pediatric Disease Designation
Importance:6/10
Sentiment:
0.70
orphan_drug_designationrare_pediatric_disease_designationgene_therapyneurometabolic_disorderultra_rare_diseaseregulatory_milestone
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on August 6, 2026 1:05 AM